| Issue |
BIO Web Conf.
Volume 108, 2024
International Scientific and Practical Conference “From Modernization to Rapid Development: Ensuring Competitiveness and Scientific Leadership of the Agro-Industrial Complex” (IDSISA 2024)
|
|
|---|---|---|
| Article Number | 04017 | |
| Number of page(s) | 8 | |
| Section | Cell Biology and Biochemistry of a Cell of a Living Organism | |
| DOI | https://doi.org/10.1051/bioconf/202410804017 | |
| Published online | 15 May 2024 | |
Investigate the impact of ICAM-2 and Neprilysin biomarkers in prostate cancer patients infected with JC virus in AL-Najaf AL-Ashraf Province
1 College of Dentistry, University of Alkafeel, Najaf, Iraq
2 University of Kufa, Kufa, Iraq
* Corresponding author: Husseinalikadhim@alkafeel.edu.iq
A total of 74 clinical samples Formalin-Fixed Paraffin-Embedded (FFPE) were collected from patients diagnosed with prostate cancer (PCa) aged between 41 and 90 years and these samples were obtained from patients treated at notable medical institutions like Al-Sadr Medical City and leading clinical laboratories in Al-Najaf City, Iraq, during the period of January to December 2023. The current study indicated the potential role of the JCV virus in provoking prostatitis, which may lead to the emergence and development of prostate cancer in males compared to males who do not suffer from viral infection. The present study showed the presence of JCV virus DNA, as the percentage of positive samples reached (11, 14.864%) compared to negative samples (63, 85.135%). The current study showed a significant increase in the level of ICAM-2 biomarker in patients with JCV-positive prostate cancer, reaching (818.500±42.748 pg/ml) compared with patients with JCV-negative, reaching (502.925±58.037 pg/ml). Neprilysin (NEP) levels in the current study were significantly high in for JCV-positive patients and those with prostate cancer, reaching (4.275±0.376 pg/ml) compared with JCV-negative patients, reaching (3.131±0.232 pg/ml).
© The Authors, published by EDP Sciences, 2024
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.